Ticker

No recent analyst price targets found for SFT.

Latest News for SFT

West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift

West Pharmaceutical Services delivered a strong 2Q26, beating on both revenue ($872.3M, +13.8% YoY) and EPS ($2.37, +$0.29 vs. consensus). WST raised full-year guidance to $3.345–$3.380B in sales and $8.85–$9.05 in EPS, reflecting confidence in sustained double-digit organic growth and margin expansion. High-Value Product components and biologics drove mix shift, with HVP now 49% of revenue and biologics up 29%…

Seeking Alpha • Jul 24, 2026
Shift4 Announces Date of Second Quarter Earnings Results and Upcoming Investor Conference Participation

CENTER VALLEY, Pa.--(BUSINESS WIRE)--Shift4 (NYSE: FOUR) today announced the date for the release of its second quarter 2026 financial results. Q2 2026 Earnings Conference Call Shift4 will release its second quarter 2026 financial results pre-market open on Thursday, August 6, 2026. Management will also host a conference call at 8:30am ET to review these results. Conference Call Details Toll-free dial-in:…

Business Wire • Jul 23, 2026
Donnelley Financial Solutions: Software Shift Drives Earnings

Donnelley Financial Solutions drives growth through compliance-focused software for regulatory filings, capital markets, and financial reporting. Software solutions now comprise 44.6% of net sales, with a long-term target of 60%, supported by strong customer adoption and AI-enhanced workflows. ActiveDisclosure and Arcflex platforms are key growth drivers, benefiting from regulatory trends and increasing recurring…

Seeking Alpha • Jul 21, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for SFT.

No House trades found for SFT.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top